Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMXI-5001 |
| Synonyms | |
| Therapy Description |
AMXI-5001 is a bifunctional inhibitor that inhibits Poly (ADP-ribose) polymerase (PARP) 1/2 and microtubule polymerization, potentially resulting in decreased cell proliferation and tumor growth (PMID: 32905466). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMXI-5001 | AMXI 5001|AMXI5001 | PARP Inhibitor (Pan) 29 | AMXI-5001 is a bifunctional inhibitor that inhibits Poly (ADP-ribose) polymerase (PARP) 1/2 and microtubule polymerization, potentially resulting in decreased cell proliferation and tumor growth (PMID: 32905466). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04503265 | Phase Ib/II | AMXI-5001 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Recruiting | USA | 0 |